Close Menu


Genomic Health discussed the status of its ongoing work with Pfizer in renal cancer and suggested it might eventually develop a companion test for Erbitux that gauges mutations "beyond KRAS."

The results of one study indicate that "there is room to improve the clarity of the information provided to customers in their personal genetic test result reports and the way the information is being delivered to them."

The "magnitude of net health benefit" from use of eight marketed tests analyzing 58 variants and 29 genes reviewed by the Evaluation of Genomic Applications in Practice and Prevention Working Group is "negligible," the expert panel wrote in a statement.

In a filing with the federal appeals court, the DoJ attempted to strike a balance between rewarding inventions that result from genomic discoveries and ensuring that discoveries of natural phenomena remain in the "storehouse of knowledge of all men." Meanwhile, it's business as usual at the USPTO until the appeals court rules on Myriad's challenged BRCA patents.

Two meta-analyses by members of the Genetic Investigation of Anthropometric Traits consortium are offering insights into the repertoire of common genetic variants behind waist-to-hip ratio and body mass index.

Through a genome-wide association study involving more than 36,000 Icelanders and follow-up studies in other populations, researchers from Decode Genetics and elsewhere have identified a SNP associated with varying levels of primary open-angle glaucoma risk in European and Chinese populations.

"The promise of genomics in the practice of medicine is great and exciting, but today the use of personal genomic tests is still not ready for prime time," a CDC official said in a video address to doctors and the general public.

Researchers from Decode Genetics and elsewhere reported that a genetic variant tied to chronic kidney disease may influence individuals' response to related diseases and environmental stressors in this population over time.

A week after being hit with a GAO report that called test results from consumer genetics firms "misleading," the big three DTC companies criticized the agency for using "unscientific" methods in its undercover investigation, but welcomed greater regulatory oversight.

During the latter part of a two-day meeting to discuss FDA's stated intent to regulate laboratory-developed tests, most speakers agreed that the FDA should bring consistency to direct-to-consumer genomic risk interpretations, and promulgate standard practices for the industry developed either by an expert advisory panel or a third-party standard-setting body.


Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.